Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Subtitle : Join us to learn how in-depth in …
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join this webinar to find out how we can help you identify promising novel leads! In this webinar, we will showcase our integrated HTS platform and share our successful track record. We will also highlight the latest advances powered by computational chemistry and AI/ML technologies.
BIO International Convention 2026
Boston, MA
J-Pharma’s LAT1 Inhibitor JPH034 Initiates Phase 1 Clinical Trial in the United States – Axcelead DDP Supported Multiple IND-Enabling Studies –
J-Pharma Co., Ltd. (“J-Pharma”) has announced that dosing …
Move your hits to candidates faster with Axcelead
Axcelead delivers quality with speed. We maintain an 84% client …
Irbesartan but not Roflumilast Ameliorates Renal Injury in a Col4a5 R471* Mutant Mouse Model of Alport Syndrome and CKD
The World Congress of Nephrology 2026
Inducible Exon Skipping After Disease Onset as a Therapeutic Strategy for CKD：Evaluation in a Patient-Derived Mouse Model of Alport Syndrome
The World Congress of Nephrology 2026